Regenerative Medicine Research Center, Sichuan University West China Hospital, Chengdu, Sichuan 610041, People's Republic of China.
Sichuan 3D Bio-Printing Institute, Chengdu, Sichuan 611731, People's Republic of China.
Biomed Mater. 2023 Feb 6;18(2). doi: 10.1088/1748-605X/acb67a.
Cell encapsulation has proven to be promising in stem cell therapy. However, there are issues needed to be addressed, including unsatisfied yield, unmet clinically friendly formulation, and unacceptable viability of stem cells after cryopreservation and thawing. We developed a novel biosynsphere technology to encapsulate stem cells in clinically-ready biomaterials with controlled microsphere size. We demonstrated that biosynspheres ensure the bioviability and functionality of adipose-derived stromal cells (ADSCs) encapsulated, as delineated by a series of testing procedures. We further demonstrated that biosynspheres protect ADSCs from the hardness of clinically handling such as cryopreservation, thawing, high-speed centrifugation and syringe/nozzle injection. In a swine full skin defect model, we showed that biosynspheres were integrated to the destined tissues and promoted the repair of injured tissues with an accelerating healing process, less scar tissue formation and normalized deposition of collagen type I and type III, the ratio similar to that found in normal skin. These findings underscore the potential of biosynsphere as an improved biofabrication technology for tissue regeneration in clinical setting.
细胞封装已被证明在干细胞治疗中具有广阔的应用前景。然而，仍有一些问题亟待解决，包括封装产量不足、无法满足临床应用的制剂要求、冻存和解冻后干细胞活力不可接受等。我们开发了一种新型生物合成球技术，可将干细胞封装于具有可控微球大小的临床即用型生物材料中。一系列测试程序表明，生物合成球可确保所封装的脂肪来源基质细胞（ADSCs）的生物活力和功能。我们进一步证实，生物合成球可保护 ADSC 免受临床处理（如冻存、解冻、高速离心和注射器/喷嘴注射）带来的硬度影响。在猪全层皮肤缺损模型中，我们表明生物合成球与目标组织整合，并通过加速愈合过程、减少疤痕组织形成以及使 I 型和 III 型胶原蛋白正常沉积来促进受损组织的修复，其比例与正常皮肤相似。这些发现强调了生物合成球作为一种改进的生物制造技术，在临床环境中用于组织再生的潜力。
